Cargando…

Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease

BACKGROUND: Recommendations on when to start enzyme replacement therapy (ERT) in children with Fabry disease (FD) differ between guidelines. In this study, kidney biopsies of a cohort of 14 untreated children and one treated child were analyzed for their morphologic changes to determine whether earl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avarappattu, Jenny, Gaspert, Ariana, Spartà, Giuseppina, Rohrbach, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10673963/ https://www.ncbi.nlm.nih.gov/pubmed/37470867 http://dx.doi.org/10.1007/s00467-023-06050-5

Ejemplares similares

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
por: Kim, Il Young, et al.
Publicado: (2021)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Observing the Observer (II): Deciding When to Decide
por: Daunizeau, Jean, et al.
Publicado: (2010)

Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy
por: Iacobucci, Ilaria, et al.
Publicado: (2023)

Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain
por: Rombach, Saskia M, et al.
Publicado: (2013)

Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series
por: Spartà, Giuseppina, et al.
Publicado: (2018)

Deciding when to exit
por: Meserve, Joy H, et al.
Publicado: (2021)

Deciding when to move
por: Sullivan, Lauren
Publicado: (2023)

Cost-effectiveness of enzyme replacement therapy for Fabry disease
por: Rombach, Saskia M, et al.
Publicado: (2013)

Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
por: Franzen, Daniel, et al.
Publicado: (2018)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
por: Li, Qian, et al.
Publicado: (2023)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease
por: Moore, David F, et al.
Publicado: (2002)

Long-Term Effect of Enzyme Replacement Therapy with Fabry Disease
por: Komori, Manabu, et al.
Publicado: (2013)

Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patients
por: Kritzer, Amy, et al.
Publicado: (2019)

Pathologic findings of Fabry nephropathy: the pivotal role of kidney biopsy
por: Shin, Jung-ho, et al.
Publicado: (2021)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Enzyme replacement therapy for Fabry disease: some answers but more questions
por: Alfadhel, Majid, et al.
Publicado: (2011)

Enzyme replacement therapy and white matter hyperintensity progression in Fabry disease
por: Stefaniak, James D., et al.
Publicado: (2018)

Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
por: Deng, Mulan, et al.
Publicado: (2022)

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy
por: Goker-Alpan, Ozlem, et al.
Publicado: (2016)

The Molecular Diagnosis Might Be Clinically Useful in Discrepant Kidney Allograft Biopsy Findings: An Analysis of Clinical Outcomes
por: Schachtner, Thomas, et al.
Publicado: (2023)

Patient's weight can decide about spending millions on enzyme replacement therapy in MPS II
por: Bik-Multanowski, Miroslaw, et al.
Publicado: (2015)

Short-Term Efficacy of Enzyme Replacement Therapy in Korean Patients with Fabry Disease
por: Choi, Jin-Ho, et al.
Publicado: (2008)

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis
por: Alegra, Taciane, et al.
Publicado: (2012)

Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy
por: Heo, Sun Hee, et al.
Publicado: (2017)

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy
por: Scionti, Francesca, et al.
Publicado: (2017)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
por: Cabrera, Gustavo, et al.
Publicado: (2017)

Fabry nephropathy: 5 years of enzyme replacement therapy—a short review
por: Barbey, Frédéric, et al.
Publicado: (2008)

Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy
por: Dutra-Clarke, Marina, et al.
Publicado: (2020)

Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease
por: Nguyen Dinh Cat, Aurelie, et al.
Publicado: (2012)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Evaluating enzyme replacement therapies for Anderson-Fabry disease: commentary on a recent report
por: Giugliani, Roberto, et al.
Publicado: (2018)

Aberrant DNA methylation of calcitonin receptor in Fabry patients treated with enzyme replacement therapy
por: Hübner, Anna, et al.
Publicado: (2015)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles
por: Boutin, Michel, et al.
Publicado: (2020)

Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease
por: Aoyama, Yumi, et al.
Publicado: (2020)

First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland
por: Nowicki, Michał, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j2pc9ta7l364cbhqpampgc2scv